Skip to main content

Liposomal amphotericin B: Clinical experience and perspectives

Publication ,  Journal Article
Gibbs, WJ; Drew, RH; Perfect, JR
Published in: Expert Review of Anti-Infective Therapy
2005

While amphotericin B deoxycholate (Fungizone®, Apothecon Pharmaceuticals) has been considered by many to be the gold standard for the treatment for numerous invasive fungal infections for over 45 years, toxicities associated with its use often necessitate treatment modification or discontinuation. Lipid-based formulations, including liposomal amphotericin B (AmBisome®, Fujisawa Healthcare, Inc.), were developed to decrease many of these toxicities while retaining broad antifungal spectrum and potency of amphotericin B. In clinical trials, liposomal amphotericin B has demonstrated efficacy comparable to that of amphotericin B deoxycholate while reducing the incidence of treatment-related nephrotoxicity, electrolyte-wasting, and infusion-related reactions. In addition, recent clinical trials have also compared liposomal amphotericin B with other antifungal classes. Acquisition costs of liposomal amphotericin B are substantially higher than those of amphotericin B deoxycholate and other antifungals. While pharmacoeconomic analyses consider outcomes and other treatment-related costs, they have yet to clearly demonstrate the cost-effectiveness of liposomal amphotericin B when compared with amphotericin B deoxycholate or other antifungal agents. This review will focus primarily on recent liposomal amphotericin B experience and attempt to put its use into perspective considering other available antifungal agents. © 2005 Future Drugs Ltd.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Review of Anti-Infective Therapy

DOI

Publication Date

2005

Volume

3

Issue

2

Start / End Page

167 / 181

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gibbs, W. J., Drew, R. H., & Perfect, J. R. (2005). Liposomal amphotericin B: Clinical experience and perspectives. Expert Review of Anti-Infective Therapy, 3(2), 167–181. https://doi.org/10.1586/14737140.3.2.167
Gibbs, W. J., R. H. Drew, and J. R. Perfect. “Liposomal amphotericin B: Clinical experience and perspectives.” Expert Review of Anti-Infective Therapy 3, no. 2 (2005): 167–81. https://doi.org/10.1586/14737140.3.2.167.
Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: Clinical experience and perspectives. Expert Review of Anti-Infective Therapy. 2005;3(2):167–81.
Gibbs, W. J., et al. “Liposomal amphotericin B: Clinical experience and perspectives.” Expert Review of Anti-Infective Therapy, vol. 3, no. 2, 2005, pp. 167–81. Scival, doi:10.1586/14737140.3.2.167.
Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: Clinical experience and perspectives. Expert Review of Anti-Infective Therapy. 2005;3(2):167–181.

Published In

Expert Review of Anti-Infective Therapy

DOI

Publication Date

2005

Volume

3

Issue

2

Start / End Page

167 / 181

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis